IP Library Granted Patent US 11,103,614
Granted Patent B2
US 11,103,614 · App. 16/085,399 · Granted Aug 31, 2021

Skin compatible composition

Inventors: Lloyd Pearce (Skipton, GB); Stewart Lee (Skipton, GB)
Assignee: TRIO HEALTHCARE LIMITED
A61L24/0094A61L24/0031A61L24/0073A61L2400/14C08K5/56C08L33/02C08L83/04C08L2203/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,103,614
App. No.
16/085,399
Granted
Aug 31, 2021
Kind
B2
Abstract

A skin compatible component attachable to mammalian skin. The component is formed as a silicone matrix comprising a polyorganosiloxane derived silicone polymer and moisture control particulate distributed within the polymer network being configured to absorb moisture from the skin. The skin compatible component may be utilised as an ostomy wafer or flange to secure an ostomy appliance to the skin and in particular peri-skin.

Claims (74)

1. A skin compatible component attachable to mammalian skin comprising:

a silicone polymer network derived from addition curing of a first part including a vinyl functionalised siloxane polymer and a second part including a silicon hydride containing crosslinker, in the presence of a metal catalyst; and

a superabsorbent particulate distributed within the polymer network at a concentration in a range of 5 to 45 wt % and having an average particle size in a range of 10 to 40 μm, the superabsorbent particulate configured to absorb moisture from the skin,

wherein the first part or the second part includes a MQ resin, and the first part or the second part includes fumed silica.

2. The component as claimed in claim 1 , wherein the average particle size of the superabsorbent particulate is in a range of 15 to 35 μm or 20 to 30 μm.

3. The component as claimed in claim 1 , wherein the superabsorbent particulate is distributed within the polymer network at a concentration in a range of 10 to 40 wt %, 15 to 35 wt % or 20 to 30 wt %.

4. The component as claimed in claim 1 , wherein the superabsorbent particulate comprises any one or a combination of the set of:

a naturally occurring hydrocolloid;

a semi-synthetic hydrocolloid; or

a synthetic hydrocolloid.

5. The component as claimed in claim 1 , wherein the superabsorbent particulate comprises any one or a combination of:

a polysaccharide;

a cellulose;

hydroxyethylcellulose;

carboxymethylcellulose;

hydroxypropylcellulose.

6. The component as claimed in claim 1 , wherein the superabsorbent particulate comprises any one or a combination of:

carboxymethyl β-glucan;

cross-linked sodium carboxymethyl cellulose;

sodium carboxymethyl cellulose; or

methylcellulose.

7. The component as claimed in claim 1 , wherein the superabsorbent particulate comprises sodium polyacrylate.

8. A method of manufacturing a skin compatible component attachable to mammalian skin comprising:

mixing a first part including a vinyl functionalized siloxane polymer with a second part including a silicon hydride containing crosslinker to form a mix, the first part or the second part including an MQ resin, and the first part or the second part including fumed silica;

incorporating within the mix a superabsorbent particulate having an average particle size in a range 10 to 40 μm; and

addition curing the mix via a metal catalyst to form a silicone polymer network,

wherein the superabsorbent particulate is distributed within the silicone polymer network at a concentration in a range of 5 to 45 wt %.

9. The method as claimed in claim 8 , wherein the superabsorbent particulate comprises any one or a combination of the set of:

a naturally occurring hydrocolloid;

a semi-synthetic hydrocolloid; or

a synthetic hydrocolloid.

10. The method as claimed in claim 8 , wherein the superabsorbent particulate comprises any one or a combination of:

a polysaccharide;

a cellulose;

hydroxyethylcellulose;

carboxymethylcellulose;

hydroxypropylcellulose.

11. The method as claimed in claim 8 , wherein the superabsorbent particulate comprises any one or a combination of:

carboxymethyl β-glucan;

cross-linked sodium carboxymethyl cellulose;

sodium carboxymethyl cellulose; or

methylcellulose.

12. The method as claimed in claim 8 , wherein the superabsorbent particulate comprises sodium polyacrylate.

13. The method as claimed in claim 8 , wherein the MQ resin is included in the mix at 2 to 8 wt % or 3 to 7 wt %.

14. The method as claimed in claim 8 , wherein the fumed silica comprises a bulk density of 0.4 to 0.8 g/mL and a Brunauer-Emmitt-Teller (BET) specific surface area of 200 to 320 mm 2 /g, 210 to 310 mm 2 /g, 230 to 300 mm 2 /g or 230 to 290 mm 2 /g.

15. The method as claimed in claim 8 , wherein the fumed silica is included within the mix at 0.2 to 2.0 wt %, 0.3 to 2.0 wt %, 0.5 to 1.5 wt % or 0.8 to 1.2 wt %.

16. The method as claimed in claim 8 , wherein the average particle size of the superabsorbent particulate is in a range of 15 to 35 μm or 20 to 30 μm.

17. The method as claimed in claim 16 , wherein the superabsorbent particulate is included within the mix at 15 to 35 wt % or 20 to 30 wt %.

18. The method as claimed in claim 8 , wherein the superabsorbent particulate comprises any one or a combination of the set of:

a naturally occurring hydrocolloid;

a semi-synthetic hydrocolloid; or

a synthetic hydrocolloid.

19. The method as claimed in claim 8 , wherein the superabsorbent particulate comprises any one or a combination of:

a polysaccharide;

a cellulose;

hydroxyethylcellulose;

carboxymethylcellulose;

hydroxypropylcellulose.

20. The method as claimed in claim 8 , wherein the superabsorbent particulate comprises any one or a combination of:

carboxymethyl β-glucan;

cross-linked sodium carboxymethyl cellulose;

sodium carboxymethyl cellulose; or

methylcellulose.

21. The method as claimed in claim 8 , wherein the superabsorbent particulate comprises sodium polyacrylate.

22. The method as claimed in claim 8 , wherein the vinyl functionalized siloxane polymer comprises a vinyl-terminated polydimethylsiloxane (PDMS).

23. The method as claimed in claim 8 , wherein the silicon hydride containing crosslinker comprises a hydride-terminated polydimethylsiloxane (PDMS).

24. The method as claimed in claim 23 , wherein the vinyl-terminated polydimethylsiloxane (PDMS) comprises a first vinyl-terminated PDMS having a mass average of 10,000 to 20,000 and a second vinyl-terminated PDMS having a mass average of 70, 000 to 100,000.

25. The method as claimed in claim 8 , wherein the vinyl functionalized siloxane polymer comprises a vinyl-terminated polydimethylsiloxane (PDMS) and the silicon hydride containing crosslinker comprises a hydride-terminated polydimethylsiloxane (PDMS).

26. The method as claimed in claim 25 , wherein the first part is included within the mix at 30 to 40 wt % or 31 to 35 wt % and the second part is included within the mix at 30 to 40 wt % or 33 to 37 wt %.

27. The method as claimed in claim 26 , wherein the superabsorbent particulate is included within the mix at 20 to 30 wt % or 22 to 28 wt %.

28. The method as claimed in claim 27 , wherein the MQ resin is included in the mix at 2 to 8 wt % or 3 to 7 wt %.

29. The method as claimed in claim 28 , wherein the fumed silica is included within the mix at 0.2 to 2.0 wt %, 0.5 to 1.5 wt % or 0.8 to 1.2 wt %.

30. The method as claimed in claim 29 , wherein the first part further comprises an organoplatinum catalyst and a silicone-vinyl containing inhibitor and the second part further comprises a vinyl-terminated polydimethylsiloxane (PDMS) and wherein the superabsorbant particulate is sodium polyacrylate.

31. A skin compatible component attachable to mammalian skin manufactured by the method of claim 8 .

Assignments (3)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 9, 2024
From: SWK FUNDING LLC
To: TRIO HEALTHCARE LIMITED
Reel/Frame 069547/0792 →
SECURITY INTEREST Recorded Jul 12, 2021
From: TRIO HEALTHCARE LIMITED
To: SWK FUNDING LLC
Reel/Frame 056829/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2018
From: PEARCE, LLOYD; LEE, STEWART
To: TRIO HEALTHCARE LIMITED
Reel/Frame 047346/0313 →
Priority Claims (2)
GB 1604308 · Mar 14, 2016 · national
GB 1703038 · Feb 24, 2017 · national
Continuity (1)
Related Publication 20190083677A1 · Mar 21, 2019
Cited By (1)
US 12,685,661